|
1) Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis: the role of homeo-stasis. Carcinogenesis. 2000; 21: 857-64
|
|
|
|
2) Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer. 2004; 44: 311-6
|
|
|
|
|
|
3) Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355: 983-11
|
|
|
|
|
|
4) Rosell R, Scagliotti G, Danenberg KD, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine / cisplatin treated advanced non-small cell lung cancer patients. Clin Can Res. 2004; 10: 1318-25
|
|
|
|
|
|
5) Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell line. Cancer Res. 2004; 64; 3761-6
|
|
|
|
|
|
6) Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed indi-vidualized therapy in advanced non-small cell lung cancer. J Clin Oncol. 2007; 25: 2741-6
|
|
|
|
|
|
7) Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-39
|
|
|
|
|
|
8) Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500
|
|
|
|
|
|
9) Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007; 352: 1817-24
|
|
|
|
|
|
10) Tracy S, Mukohara T, Hansen M, et al. Gefitinib induces apoptosis in the EGFRL858R non-small cell lung cancer cell line H3255. Cancer Res. 2004; 64: 7241-4
|
|
|
|
|
|
11) Mok T, Wu YL, Thongprasert S, et al. Phase III, randomised, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced nonsmall-cell lung cancer (IPASS). Ann Oncol. 2008; 19 suppl: abstr LBA2
|
|
|
|
|
|
12) Kobayashi K, Inoue A, Maemondo MS, et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol. 2009; 27 Suppl: abstr 8016
|
|
|
|
|
|
13) Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009; 27: 1394-400
|
|
|
|
|
|
14) Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005; 353: 133-44
|
|
|
|
|
|
15) Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23: 5856-8
|
|
|
|
|
|
16) Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786-92
|
|
|
|
|
|
17) Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplication leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316: 2528-33
|
|
|
|
|
|
18) Kokubo Y, Gemma A, Noro R, et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer. 2005; 92: 1711-9
|
|
|
|
|
|
19) Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009; 69: 3256-61
|
|
|
|
|
|
20) Soda M, Choi YL, Enomoto M, et al. Identifi-cation of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature. 2007; 448: 561-6
|
|
|
|
|
|
21) Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009; 22: 508-15
|
|
|
|
|
|
22) Shaw AT, Costa D, Mino-Kenudson M, et al. Clinicopathologic features of EML4-ALK mutant lung cancer. J Clin Oncol. 2009; 27 suppl: abstr 11021
|
|
|
|
|
|
23) Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinase in lung cancer. Cell. 2007; 131: 1190-203
|
|
|
|
|
|
24) Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF- 02341066. J Clin Oncol. 2009; 27 suppl: abstr 3509
|
|
|
|
|
|
25) Takeuchi K, Choi YL, Togashi Y. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009; 15: 3143-9
|
|
|
|
|
|
26) Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004; 22: 1382-8
|
|
|
|
|
|
27) Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 1999; 65: 576-82
|
|
|
|
|
|
28) Yamamoto K, Sato H, Fujiyama Y, et al. Contribution of two missense mutations (G 17 R and Y 486 D) of the bilirubin UDP-glycosyl-transferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Criger-Najjar syndrome type II. Biochim Biophys Acta. 1998; 1406: 267-73
|
|
|
|
|
|
29) Ando Y, Saka H, Ando M, et al. polymorphisms of UDP-glucuronosyltransferase gene and irino-tecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000; 60: 6921-6
|
|
|
|
|
|
30) Ando Y, Chida M, Nakayama K, et al. The UGT1A1＊28 allele is relatively rare in a Japanese population. Pharmacogenetics. 1998; 8: 357-60
|
|
|
|
|
|
31) Monaghan G, Foster B, Jurima-Romet M, et al. UGT1＊1 genotyping in a Canadian Inuit popula-tion. Pharmacogenetics. 1997; 7: 153-6
|
|
|
|
|
|
32) Akaba K, Kimura T, Sasaki A, et al. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine disphosphate-glucuronosyl-transferase gene in Japanese. J Hum Genet. 1999; 44: 22-5
|
|
|
|
|
33) Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999; 5: 2006-11
|
|
|
|
|
|
34) Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene with the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 2001; 7: 2832-9
|
|
|
|
|
|
35) Sugiyama E, Kaniwa N, Kim SR, et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol. 2007; 25: 32-42
|
|
|
|
|